MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including in-vitro and in-vivo diagnostics tests. This post provides some key facts about the HTA, funding and innovation payment landscape for in-vitro and in-vivo diagnostics tests in Europe.

The report presents a summary of the reimbursement situation for a number of therapeutic endoscopic procedures on esophagus in Europe, including: endoscopic mucosal resection of lesion of esophagus; endoscopic submucosal resection of lesion of esophagus; endoscopic radiofrequency ablation of lesion of esophagus; endoscopic injection sclerotherapy to varices of esophagus; endoscopic balloon dilation of esophagus; endoscopic insertion of stent into esophagus. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

The report presents a summary of the reimbursement situation for lithotripsy for kidney stones in Europe. The following types of procedure are considered: extracorporeal shock wave therapy; intracorporeal (endoscopic) lithotripsy with different type of energy used. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

The insurance company AOK Saxony-Anhalt concluded that patients are much less frequently prescribed an antibiotic after the examination via a rapid test for a bacterial cause of the infection. In more than 40% of the tested patients, the doctors waived the antibiotics prescription.

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including gastrointestinal technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for gastrointestinal devices in Europe.

In September 2019, Regional Methods Council of South East healthcare region released a report where compared the prostate artery embolization (PAE) for benign prostatic hyperplasia with the transurethral resection of the prostate (TURP). It was outlined that costs and the need for blood transfusions for PAE are lower than for TURP. The use of registries for follow-up of patients and registration of side effects is strongly recommended.

In Finland, the Health Care Services Selection Council is responsible for making recommendations regarding the research, treatment, and rehabilitation methods. Currently, PALKO is working on the only one assessment related to medical technologies - rehabilitation and treatment of lumbar spine dislocation. In the final report, the Council would conclude whether the procedure is a part of publicly funded services or not.

The German Research Foundation (DFG) has launched a new Artificial Intelligence (AI) imaging priority program "Radiomics: Next Generation Medical Imaging" (“Radiomics: Nächste Generation der medizinischen Bildgebung”). More than 8 million euros will flow into the program in the next three years. The program will be coordinated by the University Hospital Freiburg.

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including ENT technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for ENT devices in Europe.

New material codes for extraction catheters were added to the List of reimbursable devices of the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) in September 2019.

MTRC continues releasing new seminars on the topics on market access. The seminar discusses key stakeholders, money flow, reimbursement in hospital and ambulatory settings, Nomenclature of medical services, specifics of reimbursement processes and the role of HTA.

MTRC continues releasing new seminars on the topics on market access. The seminar discusses key stakeholders, money flow, reimbursement in hospital and ambulatory settings, role of DRG and fee for service model, specifics of reimbursement processes and the role of HTA.